# Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia

> **NCT06722586** · PHASE4 · RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 84 (estimated)

## Conditions studied

- Antiphospholipid (aPL)-Positive
- Thrombocytopaenia

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06722586
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-07-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06722586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06722586, "Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06722586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*